Scientific publications
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Mar Riveiro-Barciela 1 , Sabela Carballal 2 , Álvaro Díaz-González 3 , Míriam Mañosa 4 , Javier Gallego-Plazas 5 , Joaquín Cubiella 6 , Paula Jiménez-Fonseca 7 , María Varela 8 , Luis Menchén 9 , Bruno Sangro 10 , Ana Fernández-Montes 11 , Francisco Mesonero 12 , Miguel Ángel Rodríguez-Gandía 13 , Fernando Rivera 14 , María-Carlota Londoño 15
Abstract
The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs).
Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2% to 40%, the latter in patients undergoing combined ICIs therapy.
Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events.
CITATION Gastroenterol Hepatol. 2024 Jan 11:S0210-5705(23)00455-7. doi: 10.1016/j.gastrohep.2023.10.009
Our authors
